当前位置: X-MOL 学术Int. J. Hematol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
International Journal of Hematology ( IF 1.7 ) Pub Date : 2019-09-19 , DOI: 10.1007/s12185-019-02737-4
Reiki Ogasawara 1 , Daigo Hashimoto 1 , Junichi Sugita 1 , Fumihiko Yamawaki 1 , Tomoaki Naka 2 , Tomoko Mitsuhashi 2 , Shuichiro Takahashi 1 , Naohiro Miyashita 1 , Kohei Okada 1 , Masahiro Onozawa 1 , Yoshihiro Matsuno 2 , Takanori Teshima 1
Affiliation  

Nivolumab is effective in the treatment of classical Hodgkin lymphoma that relapsed after allogeneic hematopoietic stem cell transplantation (SCT) with the risk of graft-versus-host disease; however, the optimal time and dose of nivolumab administration remain to be investigated. Nivolumab binding to PD-1 masks flowcytometric detection of PD-1 by the anti-PD-1 monoclonal antibody EH12.1. Using this method, we monitored nivolumab binding on T cells after nivolumab treatment in a patient with classical Hodgkin lymphoma relapsed after allogeneic SCT. Nivolumab was effective while prolonged nivolumab binding was evident, but restoration of PD-1 staining predicted tumor relapse. Flowcytometric monitoring of nivolumab binding on T cells could be a promising biomarker for predicting tumor relapse and determining the timing of nivolumab administration.

中文翻译:

nivolumab与T细胞PD-1结合的丧失预示了霍奇金淋巴瘤的复发。

Nivolumab可有效治疗异基因造血干细胞移植(SCT)后复发的经典霍奇金淋巴瘤,且有移植物抗宿主病的风险。但是,是否需要研究诺和单抗的最佳给药时间和剂量。Nivolumab与PD-1的结合掩盖了抗PD-1单克隆抗体EH12.1对PD-1的流式细胞术检测。使用这种方法,我们在同种异体SCT复发的经典霍奇金淋巴瘤患者中监测了nivolumab治疗后nivolumab对T细胞的结合。Nivolumab是有效的,但延长了nivolumab的结合是明显的,但是PD-1染色的恢复预示了肿瘤的复发。流式细胞术监测nivolumab与T细胞的结合可能是预测肿瘤复发和确定nivolumab给药时间的有前途的生物标志物。
更新日期:2020-02-18
down
wechat
bug